BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 14, 2025
See today's BioWorld Asia
Home
» Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug
To read the full article
sign up for free
or
sign in
.
Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug
May 20, 2025
By
Marian (YoonJee) Chu
No Comments
Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.
BioWorld Asia
Deals and M&A
License
Gene therapy
Asia-Pacific
U.S.
FDA
